Signet Financial Management LLC Has $562,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Signet Financial Management LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,058 shares of the medical research company’s stock after selling 19 shares during the quarter. Signet Financial Management LLC’s holdings in Thermo Fisher Scientific were worth $562,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. WCM Investment Management LLC increased its holdings in Thermo Fisher Scientific by 0.3% in the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after purchasing an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. increased its holdings in shares of Thermo Fisher Scientific by 21.4% during the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares in the last quarter. DMC Group LLC increased its holdings in shares of Thermo Fisher Scientific by 16.5% during the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after acquiring an additional 84 shares in the last quarter. S. R. Schill & Associates increased its holdings in shares of Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 792 shares in the last quarter. Finally, Check Capital Management Inc. CA bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $219,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the topic of several analyst reports. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Evercore ISI lifted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $601.56.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the sale, the chief executive officer now owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 in the last ninety days. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.6 %

Shares of TMO stock opened at $554.65 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The stock’s 50-day moving average price is $571.67 and its 200-day moving average price is $526.87. The stock has a market capitalization of $211.72 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the previous year, the business earned $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.